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Abstract (amended) 
Background: Clostridium difficile infection (CDI) causes substantial morbidity and healthcare 
expenditure across Europe. UK prevalence of C. difficile PCR ribotype 027 (NAP1) has declined 
dramatically recently and other ribotypes have emerged, including ribotype 002 (CD002); now 
the most prevalent UK ribotype. CD002 is also responsible for CDI in many countries across 
Europe, including: France, Germany, Ireland, and The Netherlands. We assessed the in vitro 
phenotypic characteristics of CD002 from across Europe to determine traits that may contribute 
to its increasing clinical prevalence.  
 
Material/methods: Sixty CD002 were studied: UK isolates from 2007-2008 (geographically 
distinct, N=15), UK isolates from 2011-2013 (19 locations, N=22), and non-UK European isolates 
from 2012-2014 (N=23, 20 locations). Antimicrobial susceptibilities (13 antimicrobials) were 
evaluated using an agar incorporation method. Maximum specific growth rates (μmax) were 
calculated and cytotoxin titres (log10-relative units, RU) determined using Vero cell cytotoxicity 
assays. Biofilm formation was quantified using 96-well microtitre plate assays and sporulation 
capacities assessed in liquid culture by quantifying spore-formation over 120 h (CFU/mL).   
 
Results: All isolates were susceptible metronidazole, vancomycin, tetracycline and linezolid (MICs 
≤2 mg/L). Clindamycin resistance (MIC ≥8 mg/L) was more common in non-UK CD002 (30%) than 
UK strains (5-13%). Resistance to erythromycin, clarithromycin, nitrofurantoin, chloramphenicol, 
and moxifloxacin was uncommon (5-7%). MICs for penicillin’s remained below resistance 
breakpoints, regardless of origin, in all but one isolate (ampicillin MIC 2 mg/L). All CD002 were 
resistant to trimethoprim (MICs >128 mg/L) and ciprofloxacin (MICs ≥8 mg/L). One MDR strain 
(UK, 2007) was observed that was macrolide, fluoroquinolone, ampicillin, and nitrofurantoin 
resistant. Significantly faster μmax was seen in non-UK CD002 (0.92 ±0.058 h
-1) than recent/older 
UK strains (0.76 ±0.063/0.69 ±0.028 h-1 respectively) (P<0.001). Cytotoxin production did not 
differ significantly (median titres 2-3 RU) between CD002 groups. Recent UK/non-UK CD002 
formed significantly greater biofilms by 3 days than asynchronous UK CD002 (P<0.001). 
Sporulation studies demonstrated that recent UK/non-UK CD002 sporulated more at 24 h than 
older UK CD002; 18.6-fold/31.2-fold respectively (P<0.05), but by 120 h sporulation did not differ. 
 
Conclusions: Recent CD002 from diverse European locations were assessed for traits that may 
help to explain emergence of CD002 in the UK and compared to asynchronous CD002. Previous 
studies demonstrated elevated CD002 μmax compared to hypervirulent ribotypes 027/078; and 
the present study demonstrated that recent non-UK CD002 μmax were significantly further 
elevated vs. UK isolates. Non-UK CD002 were more clindamycin resistant, but other antimicrobial 
susceptibilities were similar between CD002 groups. Recent CD002 demonstrated significantly 
increased sporulation capacities at 24 h and more extensive 3 day biofilm formation compared to 
asynchronous UK CD002, which could enhance their survival and transmission early in an episode 
CDI. Further phenotypic and genetic studies are required to evaluate further characteristics of 
CD002 that may be associated with its emergence in the UK. 
 
Introduction 
• Despite improved clinical management strategies for CDI, healthcare costs for treating CDI 
remain high and have been estimated in the USA at $1.1-3.2 billion [1-2].  
• C. difficile hypervirulence has been attributed to ribotypes 027 & 078 due to increased CDI 
severity [3-4]. 
• UK: national distribution of C. difficile ribotypes is monitored by the C. difficile Ribotyping 
Network and CD002 is now the most common ribotype in the UK, with prevalence in 2015 of 
14.5% (Q1), 18.4% (Q2), 15.0% (Q3), and 16.4% (Q4) of isolates submitted to CDRN [5] 
• Europe: CD002 has been isolated in: France, Germany, Ireland, and The Netherlands. 
 
Materials & Methods 
C. difficile strains (Figure 1) 
• 60 CD002 : UK isolates, 2007-2008 (geographically distinct, N=15); UK isolates, 2011-2013 (19 
locations, N=22); and non-UK European isolates, 2012-2014 (N=23, 20 locations).   
Antimicrobial susceptibility testing 
• Agar incorporation MICs on Wilkins-Chalgren agar with 104 C. difficile cfu per spot 
Biofilm quantification 
• Culture medium: BHI+0.1% (w/v) L-cysteine HCl + 0.5% (w/v) yeast extract + 0.1M glucose 
(BHISG). Quantification: 3 and 6 days, crystal violet staining (OD590) 
Growth rate analysis & cytotoxin production  
• Growth rate analysis: OD600 determined at time between 3-6 hours during log growth 
• Cytotoxin: Vero cell cytotoxicity assay of BHIS culture supernatants from 72 h cultures  
• Cytotoxin titres expressed as log10 relative units (RU) 
Figure 1. Distribution of CD002 isolates evaluated in this study. Non-UK CD002 makers are correct to 
country but not exact geographical location (Contour coloration is not relevant to this study map 
acquired from www.nasa.gov) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results/Conclusions 
• Antimicrobial susceptibilities (Figure 2) did not differ significantly between CD002 
from different locations or lineages; therefore, these are unlikely to be a driver for 
the emergence of CD002 in the UK. 
• Biofilm formation was significantly enhanced in more recent CD002 isolates(Figure 
3, P<0.001) after 3 days, although not significantly greater after 6 days. 
• Non-UK CD002 grew significantly (P<0.001) faster than UK strains (Figure 4), 
regardless of year of isolation. 
• All CD002 had elevated growth rates compared with hypervirulent ribotypes  027 & 
078 (data not shown), which could confer a competitive advantage. 
• More recent CD002 sporulated to a significantly greater degree after 24 hours 
compared with older UK isolates (Figure 6, P<0.05) and toxin titres were 
comparable with those for hypervirulent ribotypes (data not shown). 
• Enhanced CD002 sporulation, as observed in prior studies [6], & elevated biofilm 
formation may benefit recent isolates and provide a competitive advantage  in vivo; 
studies of the kinetics of toxin production are warranted. 
Results 
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Figure 3. C. difficile ribotype 002 
mean (±SE) biofilm production 
(OD590) in a microtitre plate assay 
with crystal violet staining after 3 
and 6 days anaerobic incubation 
in BHISG. ***significant 
difference P<0.001. 
 
Figure 4. Maximum specific 
growth rates (μmax) of CD002 (h
-1, 
mean ±SE) in BHIS during 
exponential growth. 
***significant difference P<0.001. 
Figure 2. Antimicrobial agent 
geometric mean (GM) MICs 
(mg/L) for CD002 using agar 
incorporation MIC testing. PEN, 
penicillin G; AMP ampicillin; LZD, 
linezolid; MXF, moxifloxacin; 
CHL, chloramphenicol; CLA, 
clarithromycin; ERY, 
erythromycin; VAN, vancomycin; 
MTZ, metronidazole; NFT, 
nitrofurantoin; CLI, clindamycin; 
TET, tetracycline; CIP, 
ciprofloxacin. Differences 
between groups are non-
significant. 
Figure 5. Percentage (%) of 
CD002 isolates demonstrating 
cytotoxin titres of 2 RU, 3 RU, and 
4RU after 72 hours following 
culture in BHIS. Differences 
between groups are non-
significant. 
Figure 6. Spore formation 
(cfu/mL) by CD002 in BHIS 
broth after 24 hours 
incubation. 
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